We are single-minded in our pursuit of a cure for Glioblastoma Multiforme (GBM), and invite you to explore our Investor Relations page to understand the financial promise that aligns with our life-changing mission.
Quarterlies
View All Financial FilingsNew Releases
View AllCNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
20 February, 2025CNS Pharmaceuticals Inc. Participates in the Virtual Investor Top 5 for '25 On Demand Conference
19 February, 2025Events
View AllVirtual Investor "Top 5 for ‘25" On-Demand Conference
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day
Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)
Your email alerts were set.
The following alerts could not be set:
Resources
Analyst Coverage
CNS Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding CNS Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CNS Pharmaceuticals, Inc. or its management. CNS Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Company
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.